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The aim of this study is to systematically examine the
proportion of accurate readings attained by automatic
digital blood pressure (BP) devices in published valida-
tion studies. We included studies of automatic digital BP
devices using recognized protocols. We summarized
the data as mean and s.d. of differences between
measured and observed BP, and proportion of measure-
ments within 5mmHg. We included 79 articles (10783
participants) reporting 113 studies from 22 different
countries. Overall, 25/31 (81%), 37/41 (90%) and 34/35
(97%) devices passed the relevant protocols [BHS, AAMI
and ESH international protocol (ESH-IP), respectively].
For devices that passed the BHS protocol, the propor-
tion of measured values within 5mmHg of the observed
value ranged from 60 to 86% (AAMI protocol 47–94% and
ESH-IP 54–89%). The results for the same device varied
significantly when a different protocol was used (Omron
HEM-907 80% of readings were within 5mmHg using the
AAMI protocol compared with 62% with the ESH-IP).
Even devices with a mean difference of zero show high
variation: a device with 74% of BP measurements within
5mmHg would require six further BP measurements to
reduce variation to 95% of readings within 5mmHg.
Current protocols for validating BP monitors give no
guarantee of accuracy in clinical practice. Devices may
pass even the most rigorous protocol with as few as
60% of readings within 5mmHg of the observed value.
Multiple readings are essential to provide clinicians and
patients with accurate information on which to base
diagnostic and treatment decisions.
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Introduction
Hypertension is an important worldwide public
health problem and is a major risk factor for
cardiovascular disease, the leading cause of death
and disability worldwide.
1,2 Testing for hyperten-
sion is the most commonly performed screening test
in medical practice and is important not least
because individuals with a normal blood pressure
(BP) at the age of 50 still run a 90% life-time risk of
developing hypertension.
3 Furthermore, trial evi-
dence indicates that even small differences in
systolic BP of 2–4mmHg are clinically important,
thus accurate measurement is vital.
4–6
Errors in measurement occur through three main
sources: device errors, user errors and patient
errors.
7 Device errors are potentially the most
fundamental of these three sources, and, in parti-
cular, accurate measurement is underpinned by the
requirement for an instrument that measures pres-
sure accurately in patients across the range of
pressures.
8 For many years, the standard instrument
for BP measurement was a mercury sphygmomano-
meter, but in recent years this has been superseded
in many clinical settings by automated electronic
devices.
The need to validate the accuracy of such devices
has led to the development of various protocols.
(Box 1).
9,10 These protocols stipulate the minimum
testing population with an acceptable range of mean
and s.d. of errors or an s.d. below a threshold, which
is dependent on the level of mean difference, but do
not specify the proportion of individuals within
those populations that should have accurate read-
ings.
11 However, it is possible for a BP monitor to
meet the above validation criteria, but still record BP
measurements in error by 45mmHg in half of the
individuals assessed.
6 It has, therefore, been argued
that validation standards should be based, in part,
on the percentage of individual readings within an
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12,13 To understand the potential
effect of such a change in policy, we aimed to
systematically examine the proportion of accurate
readings attained by automatic digital BP devices in
published clinical validation studies.
Methods
Eligibility and search strategy
We included all published studies of automatic
digital BP devices that (1) validated studies of BP
devices using a recognized protocol in a clinic
setting or in the community; (2) used a sphygmo-
manometer with upper arm BP measurement; (3)
included adult patients (X18 years of age) with no
significant severe intercurrent health problems and
(4) included data on the mean and s.d. of the BP
difference between calibrated standard sphygmo-
manometer (mercury or random-zero sphygmomano-
meters) and (semi-)automatic (oscillometric or
aneroid) sphygmomanometer. There were no lan-
guage restrictions.
Reasons for study exclusion were devices used in
special clinical situations (for example pregnancy, at
altitude, during exercise, in trauma patients, neo-
nates, children and serious diseases), measurements
not from upper arm BP monitoring devices (for
example wrist and ABPM), comparison with other
sphygmomanometers (for example direct central
pressure and ambulatory intra-arterial pressure)
and published papers reporting no mean difference
or s.d.. We searched Ovid versions of MEDLINE and
EMBASE, and Cochrane Library through Wiley
Interscience from January 1989 to June 2008.
Medical Subject Headings and synonym terms used
were sphygmomanometer, BP, hypertension, cali-
bration and monitor device. We also searched the
reference lists of identified papers and reviews.
Data abstraction
Two authors reviewed the titles and abstracts of all
identified articles and selected full-text papers.
Articles clearly not meeting the criteria were
excluded at this stage. The remaining articles were
then reviewed in detail by three authors for inclu-
sion. We extracted data on the percentage of BP
measurements within 5mmHg, mean and s.d. of
difference between calibrated standard sphygmo-
manometer and (semi-) automatic sphygmoman-
ometer. We also obtained information on detail of
process, including study design, sample size, device
characteristics and the relevant guidelines used to
assess the device accuracy.
One author (YW) extracted data and this was
rechecked by a second author (CH) independently,
disagreements were resolved by discussion with a
third author (RP). The reviewers were not masked to
any aspect of the studies (for example journal type,
author names or institution).
Data analysis
We used Review Manager (RevMan) Version 5.0.
Copenhagen: The Nordic Cochrane Centre, The
Cochrane Collaboration, 2008 for the statistical
analysis and forest plots (sorted by mean effect and
device type for systolic BP and diastolic BP).
We summarized data as mean and s.d. of differ-
ences between measured and observed BP (the
observer control measurement used in the protocol),
and proportion of measurements within 5mmHg of
observed BP and ordered the rows of the figures by
the percentage of measurements with errors
o5mmHg. When this information was not avail-
able, we replaced it by a bias-corrected modelled
value, defined as 0.27þ0.76 P, where P is the
Box 1 Summaries of protocols for validating automated
sphygmomanometers
British Hypertension Society Protocol (1993)
K Sample size: 85 subjects with 3 measurements on each
K Selection: to represent a range of blood pressures from
o90/60mmHg to 4180/110mmHg, arm
circumference and other characteristics by unbiased
sampling
K Comparison: sequential measurement in the same arm
K Criteria: the acceptable differences
a vary according to
the true blood pressure—see full protocol for details
K Statistical methods: treat as 255 independent
measurements
Association for the Advancement of Medical
Instrumentation (American National Standard) (2002)
b
K Sample size: at least 85 subjects with 3 measurements
each
K Selection: a range of blood pressures, at least 10%
o100/60mmHg and 10% 4160/100mmHg, and 10%
to be on subjects on arm sizes o25cm and 10%
435cm, other characteristics by unbiased sampling
K Comparison: simultaneous measurement in the same
arm
K Criteria: difference has mean o5mmHg and s.d.
o8mmHg
K Statistical methods: treat as 255 independent
measurements
c
European Society of Hypertension International Protocol
(2002)
K Sample size: 33 subjects with 3 measurements each
K Selection: in three blood pressure bands from o130/80
to 4160/100mmHg, with additional requirements on
age and sex
K Comparison: sequential measurement in the same arm
K Criteria: at least 2/3 of subjects have at least 2/3 of
differences o5mmHg; no 43 out of 33 subjects have
differences 45mmHg
K Statistics: account for both subject level and
observation level variation (see ‘criteria’)
aThese summaries refer to the protocols for validating automated
sphygmomanometers against auscultatory measurements in the
general adult population.
bAlso provides alternative, approximately equivalent, criteria to
be used with an alternative statistical method.
c‘Differences’ refer to differences between the test value and
comparison values, usually taken by an auscultatory method by
two independent observers.
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distribution, and the bias correction coefficients
(0.27 and 0.76) were derived by linear regression on
the trials that report all outcomes. We analysed the
effect of year of protocol by separating studies into
four groups (before 1995, 1996–2000, 2001–2005
and after 2006) and used analysis of variance and
the Z
2 to estimate the amount of variation explained
by year of protocol These calculations were per-
formed using STATA (Intercooled STATA 10 for
Windows).
We also calculated the additional number of
measurements required assuming a normal distribu-
tion for a selection of devices to achieve 95% of
readings within 5mmHg based on the assumption
of a mean difference equal to zero and a dispersion
of 2.5mmHg (similar to the top-rated device for
each protocol).
Results
From 5912 potentially relevant records, 79 articles
(10783 participants) reporting 113 studies (includ-
ing subgroups for different devices and protocols)
met the eligibility criteria (Figure 1). Of these, 96
studies were recommended devices by the various
protocols, 13 were not recommended and 14 devices
were validated in the community (including six not
recommended by the protocol).
Studies were from 22 different countries: US (23);
UK (20); France (15); Italy (10); Ireland and Poland
(6 each); Japan (5); Canada (4); Russia, Germany
and Turkey (3 each); Denmark, Greece, Spain and
Switzerland (2 each); and Argentina, Brazil, China,
Israel, Netherlands, Sweden and Tanzania (1 each).
Studies used five different protocols for validating
devices: 35 used the ESH international protocol
(ESH-IP), 9 the BHS protocol, 19 ANSI/AAMI
protocol and 22 used both the BHS and ANSI/AAMI
protocols. The results from these are presented in
Figures 2–4, respectively. A further 16 studies used
different protocols: 3 the American Heart Associa-
tion BP measurement guidelines, 2 the Health
Insurance Portability and Accountability Act proto-
col and 11 studies did not state which protocol they
used. All of these 16 were excluded from the present
analysis, and on re-analysis, four aneroid devices
were removed from the analysis.
For each study, the citation, device tested and
mean and s.d. of differences are shown, together
with the reported proportion of measurements
within 5mmHg of the observed value. Some studies
and/or devices appear more than once in which
results were reported using different sampling
schemes and/or protocols or where more than one
group validated a device.
Overall, 25/31 (81%, 95% CI: 67–95%), 37/41 (90,
81–99%) and 34/35 (97, 92–99.5%) of devices
passed the relevant protocol (BHS, AAMI and
ESH-IP, respectively). No particular pattern was
seen either in terms of the date of assessment or of
manufacturer in terms of likelihood of a machine in
terms of accuracy (data not shown).
Devices passing the BHS protocol had between 60
and 86% of measured values within 5mmHg of the
observed value (Figure 2). Devices failing the BHS
protocol (marked with a w) had between 35 and 59%
of test device values within 5mmHg. Devices
passing the AAMI protocol had between 47 and
94% of measured values within 5mmHg of the
correct value (Figure 3) and for the four devices
failing 36–58% within 5mmHg. For the ESH-IP
protocol devices passing the protocol, it had 54–
89% within 5mmHg, and for the one device
reported to fail the International protocol, 52% were
within 5mmHg (Figure 4).
Some studies appear twice as they undertook the
protocol, but using different techniques. For exam-
ple, in the Reinders’ study,
14 when automated
measurements using the BHS protocol were taken
simultaneously with the reference standard, 96%
were within 5mmHg of the reference value; when
taken sequentially, 80% were within 5mmHg.
In devices tested in community/clinic-based stu-
dies (studies performed from a population-based
perspective), between 35 and 46% of measured
values were within 5mmHg of the observed value.
We found only two devices tested using both a
protocol and in the community. For the Omron
HEM-705CP, 86% of measurements were within
5mmHg of the observed value under the BHS
protocol
15 compared with 46% within 5mmHg in
the community-based study.
16 For the IVAC model
4200, these figures were 59% under the BHS
5912 potentially relevant records
identified and screened
3356 potentially relevant records
screened by two reviewers
241 records retrieved in full text for
more detailed assessment
2556 duplicate records excluded
3115 records excluded because
clearly not relevant
162 excluded because did not meet
detailed inclusion criteria
79 records in the systematic review
Figure 1 Flowchart of search results.
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17
When we studied the performance of the monitors
for diastolic BP, results were broadly similar.
Figure 5 shows the mean and single s.d. of errors
in BP monitors in repeated studies of the same
monitor using either the same or different protocols.
The results for the same device could vary substan-
tially when a different protocol was used. For
example, the Omron HEM-907 device could vary
by 18% of readings within 5mmHg depending on
which protocol was used: 80% (using the AAMI
protocol)
18 compared with 62% (ESH-IP protocol).
19
The same device could also vary by 22% of readings
within 5mmHg when the same protocol was used:
62% (El Assaad 2002)
19 compared with 84% (De
Greef 2007).
20
There was no significant difference between the
three different protocols (P¼0.20). However, the
year of protocol was significantly correlated with the
proportion of measurements (r¼0.257, Po0.01).
Overall, 19% of the variation could be explained
by changes over time (Z
2¼2581.11/13600.77¼0.19;
F¼6.513, Po0.001). Subgroup analysis by protocol
showed the ESH-IP to be the contributor to this
correlation (the majority of its studies were later
with 64% after 2005), whereas the BSH and AAMI
(earlier studies) were not.
Even if a given device could be improved to have a
mean zero, it would still be necessary to reduce the
variation. For example, for a device with 74% of BP
measurements o5mmHg [the Welch Allen Vital
Signs (s.d.: 5)], a further six BP measurements
would be required to reduce the variation, so that
95% of readings fall within 5mmHg. To obtain the
same precision for the Pharma Smart PS-2000
(s.d.: 7), a device with 66% o5mmHg, a further
11 measurements are required (based on the
assumption that in each individual the BP differ-
ences between the tested device and the reference
method are random). For the ESH-IP protocol when
using a device with 81% o5mmHg [Artasan CS410
(s.d.: 5.9)], a further eight BP measurements are
required to reduce variation, so that 95% of readings
are within 5mmHg; whereas for the Omron M6
Comfort (s.d.: 7.4) with 68% o5mmHg, a further 12
measurements are required. The mean difference
Study or Subgroup
Mean SBP Difference±SD
(% <5mmHg)
Mean DBP Difference±SD
(% <5mmHg) Mean SBP Difference±SD
Imai 1995 (Korotkoff sound)*
Iglesias 2002
Iglesias 2002*
Zaetta 2007
Kobalava 2005
Bortolotto 1999*
Kobalava 2005
De Greeff 2007*
Jones 2001*
Imai 1995 (cuff-oscillometric)*
De Greeff 2007*
Coleman 2006*
Mano 2002*
Coleman 2008*
De Greeff 2008*
Verdecchia 2004
Westhoff 2008
Bortolotto 1999*
Alpert 2004
Cuckson 2002*
Verdecchia 2006
De Greeff 2008*
Alpert 2007*
Golara 2002*
-0.6±3.4(86)
-1.1±4.7(86)
-1.3±5.3(83)
0.4±5.0(81)
-1.9±4.3(79)
0.8±5.0(76)
-1.9±4.9(76)
-0.3±6.9(75)
-1.0±5.0(74)
-0.6±6.1(72)
0.5±7.3(72)
0.6±6.0(70)
0.0±6.3(69)
-0.8±6.5(69)
-2.4±6.0(68)
-1.0±7.1(68)
-1.9±6.6(66)
-1.0±7.0(66)
0.2±8.0(66)
0.2±7.0(65)
-1.7±7.4(64)
0.4±7.7(63)
1.5±7.6(62)
-0.9±7.2(60)
-2.1±7.1(60)
1.6±7.4(59)
0.0±8.0(59)
-3.7±7.5(47)
-5.5±8.3(39)
-5.5±8.5(36)
5.3±6.7(35)
-0.2±4.0(86)
-0.4±4.0(91)
-0.5±3.9(91)
-2.0±6.0(71)
-1.4±4.0(87)
0.4±8.0(71)
-1.2±4.2(83)
-4.0±5.9(60)
-3.0±4.0(72)
0.0±4.9(72)
-2.1±7.8(60)
-3.2±6.6(61)
-3.8±6.2(63)
1.3±5.0(70)
0.9±6.3(73)
-1.4±7.6(69)
0.0±5.8(65)
-6.0±7.0(47)
0.9±8.0(74)
-0.1±6.7(66)
-2.1±6.3(68)
0.3±8.2(65)
-1.2±6.1(71)
-2.2±6.7(60) 
-2.4±5.8(70)
2.0±7.5(54)
-3.0±7.7(56)
-4.8±5.6(54)
-6.8±6.8(36)
-3.0±5.9(60)
7.5±7.1(43)
Device Name 
O'Brien 1993  
Braam 2002
Shahriari 2003*
Shahriari 2003*
Dieterle 1998*
Beaubien 2002*
Shuler 1998*
Terumo ES-H51
Omron HEM-705 CP
Omron M1
SAA-102
A&D UA-704
Omron HEM-722C
A&D TM-2564G
Dinamap ProCare monitor
Welch Allyn  Vital Signs
Terumo  ES-H51
Health and Life device (HL888HA)
Omron 705IT (HEM-759-E)
DIXTAL DX-2710
Omron M7 (HEM-780-E)
Tensoval duo control 
A&D UA-774 (UA-767Plus)
Stabil-O-Graph
Dinamap 8100
Omron HEM-735C
Pharma-Smart PS-2000
Microlife BP 3BTO-A
A&D UA-705
Rossmax (ME 701 series)
Welch Allyn Spot Vital Signs Lxi
Omron-MIT
IVAC model 4200
Dinamap1846XT
Visomat OZ2
A&D UA 777
Omron M4
Welch Allyn Signs Monitor 52000
Figure 2 Means and s.d. of errors in systolic BP in devices passing, or failing (marked dagger), the British Hypertension Society
protocol.
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Journal of Human Hypertensionbetween devices that passed the protocols was
relatively stable: BHS range:  2.4–1.5mmHg, AAMI:
2.8–2.7mmHg and ESH-IP:  3.2–2.0mmHg.
Discussion
Devices that passed international validation proto-
cols for BP accuracy vary greatly in quality. Taking
‘percentage of readings within 5mmHg of the
observed value’ as a measure of quality, we found
wide variations in quality among devices that
passed protocol testing, whether the protocol was
BHS, AAMI or ESH-IP, with slight improvements in
performance using the ESH-IP protocol. This is a
reflection in part of the numbers of individuals
required to fulfil the protocols, which affects their
ability to distinguish between machines of differing
accuracies: the BHS protocol requires testing on 85
patients, and, therefore, has the power to distinguish
differences between devices of 415%, whereas the
international protocol requires only 33 patients (less
than the other protocols), and can only detect
differences between devices of 424%.
Moreover, devices passing a protocol are not
necessarily more accurate than devices that failed,
and devices that pass may perform substantially
worse when tested in a community setting. In
addition, a device that passes validation does not
mean that it provides accurate readings in all
patients; inaccuracy is more likely in older and
diabetic patients.
21,22
Study or Subgroup
Mean SBP Difference±SD
(% <5mmHg)
Mean DBP Difference±SD
(% <5mmHg) Mean SBP Difference±SD
Zaetta 2007 (AAMI method 2)
Yarows 2007 (AAMI method 2)
Yarows 2007 (AAMI method 1)
Imai 1995 (Korotkoff sound)*
O'Brien 1990
Iglesias 2002*
Zaetta 2007 (AAMI method 1)
Rogoza 2000*
White 2001
Foster 1994*
Bortolotto 1999*
De Greeff 2007*
Jones 2001*
Wright 2001*
Alpert 2004 (AAMI method 2)
Imai 1995 (cuff-oscillometric)*
De Greeff 2007*
O'Brien 1990
Anwar 1998
Coleman 2006*
Mano 2002*
Coleman 2008*
De Greeff 2008*
Alpert 2004 (AAMI method 1)
Bortolotto 1999*
Orr 2005
White 2003
Cuckson 2002*
Orr 2005
De Greeff 2008*
Orr 2005
Mattu 2001*
Alpert 2007*
Golara 2002*
Shuler 1998*
Beaubien 2002*
Shahriari 2003*
0.1±3.2(94#)
-0.9±4.0(93)
-0.6±4.3(93)
-0.6±3.4(86)
-0.1±4.4(84#)
-1.3±5.3(83)
0.1±4.6(82#)
0.0±5.4(82)
1.6±4.4(80)
-1.2±5.1(77#)
0.8±5.0(76)
-0.3±6.9(75)
-1.0±5.0(74)
-0.2±5.1(74)
0.1±5.9(73#)
-0.6±6.1(72)
0.5±7.3(72)
-2.8±5.4(72#)
0.8±6.6(71)
0.6±6.0(70)
0.0±6.3(69)
-0.8±6.5(69)
-2.4±6.0(68)
0.1±7.0(67#)
0.2±8.0(66)
-1.2±7.6(64#)
-0.1±7.5(64)
-1.7±7.4(64)
-0.4±7.7(64#)
1.5±7.6(62)
2.7±7.8(62#)
-0.6±7.0(61)
-0.9±7.2(60)
-2.1±7.1(60)
1.6±7.4(59)
0.0±8.0(59)
-2.2±9.2(58#)
-2.6±9.8(56#)
-3.7±7.5(47)
-5.5±8.3(39)
-5.5±8.5(36)
-2.7±3.5(83#)
-0.5±3.9(92)
-0.5±4.3(92)
-0.2±4.0(86)
-4.3±4.6(68#)
-0.5±3.9(91)
-2.7±5.2(73#)
-0.4±4.8(80)
3.5±4.6(64)
-4.4±5.4(65#)
0.4±8.0(71)
-4.0±5.9(60)
-3.0±4.0(72)
-1.4±4.7(78)
-0.3±6.1(72#)
0.0±4.9(72)
-2.1±7.8(60)
-4.2±4.8(68#)
1.0±5.5(77)
-3.2±6.6(61)
-3.8±6.2(63)
1.3±5.0(70)
0.9±6.3(73)
-0.3±6.6(69#)
0.9±8.0(74)
-1.4±7.5(64#)
2.5±5.2(71)
-2.1±6.3(68)
-1.5±6.7(68#)
-1.2±6.1(71)
0.4±7.4(65#)
-1.5±4.8(82)
-2.2±6.7(60)
-2.4±5.8(70)
2.0±7.5(54)
-3.0±7.7(56)
-3.0±11.3(52#)
0.0±9.2(59#)
-4.8±5.6(54)
-6.8±6.8(54#)
-3.0±5.9(69#)
Device Name
SAA-102
SAA-102
HoMedics BPA-300
Terumo ES-H51
Nissei Analogue Monitor
Omron M1
A&D UA-767
Omron HEM-907
Omron HEM-706
Omron HEM-722C
Dinamap ProCare monitor
Welch Allyn  ‘Vital Signs’
BPM-100
Pharma-Smart PS-2000
Terumo ES-H51
Health and Life (HL888HA)
Philips HP5308
Omron HEM-737 IntelliSense
Omron 705IT (HEM-759-E)
DIXTAL DX-2710
Omron M7 (HEM-780-E)
Omron HEM-735C
Tensoval duo control
Pharma-Smart PS-2000
MABIS Smart Read (04-310-001)
Accutorr PlusTM (Datascope Corp.)
Microlife BP 3BTO-A
MABIS Smart Speed Plus
Rossmax (ME 701 series)
MABIS Semi-Automatic
BPM-100Beta
Welch Allyn Spot Vital Signs Lxi
Omron-MIT
IVAC model 4200
Dinamap 1846XT
Philips HP5306/B
Omron HEM-400C
Omron M4
Visomat OZ2
A&D UA 777
HoMedics BPA-300
O'Brien 1990
O'Brien 1990
Dieterle 1998*
Shahriari 2003*
Figure 3 Means and s.d. of errors in systolic BP in devices passing, or failing (marked dagger), the AAMI protocol.
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Journal of Human HypertensionStudy or Subgroup  Device Name Mean SBP Difference±SD
(% <5mmHg)
Mean DBP Difference±SD
(% <5mmHg)
Mean SBP Difference±SD
Altunkan 2007 (adults)
Belghazi 2007 -1.4±8.6(87) -0.1±3.5(94)
Omboni 2007 0.2±3.6(86) 0.2±3.9(86)
De Greeff 2007 -1.4±4.8(86) -0.9±3.5(91)
Cotte 2008 0.7±4.4(85) -3.6±4.0(74)
Belghazi 2007 1.6±4.2(85) 0.5±2.8(92)
Topouchian 2006 -0.8±4.2(84) -1.9±3.8(85)
El Assaad 2003 -0.2±4.5(84) -2.0±4.8(75)
Haensel 2005 -0.7±4.6(84) -0.8±4.4(81)
De Greeff 2007 0.1±5.1(84) -1.9±4.2(81)
Belghazi 2007 -1.4±5.5(84) -0.4±4.8(81)
Altunkan 2007 (obese) 1.7±4.8(83) -0.8±4.3(81)
Pini 2008 -0.9±5.9(81) -1.0±3.1(93)
Reinders 2006 -2.5±5.4(79) 0.5±4.5(77)
Oregon Scientific BPW810 Li 2006 -2.2±4.8(78) -0.5±3.7(82)
De Greeff 2008 -1.5±5.3(78) 1.5±6.1(78)
Topouchian 2005 -0.9±5.2(77) -1.7±4.7(80)
Wilton 2006 -3.2±3.8(77) -1.8±2.9(88)
Longo 2003 1.0±5.3(77) 0.7±5.3(79)
Altunkan 2008  1.4±5.3(77) -1.4±4.5(78)
Nolly 2004 -1.6±4.8(76) 2.2±3.8(79)
Stergiou 2007 -0.3±5.6(76) -2.4±4.8(75)
Topouchian 2005 -1.3±5.6(75) -0.4±4.8(82)
Longo 2002 2.0±5.0(73) 1.0±3.0(94)
Westhoff 2008 0.0±5.6(73) 1.0±5.7(76)
Stergiou 2006 -2.0±6.0(72) -3.1±4.1(72)
De Greeff 2008 -0.1±6.2(71) -2.8±5.3(73)
Viera 2007 0.5±7.7(71) 0.4±4.7(77)
Coleman 2005 -1.2±5.7(69) -1.6±4.7(76)
El Assaad 2003 -0.9±5.8(69) -0.8±4.8(84)
Belghazi 2007 -2.1±7.4(68) 0.1±4.9(74)
Alpert 2007 -1.6±6.7(67) -0.1±4.0(83)
El Assaad 2002 -1.0±7.0(62) -5.0±6.0(53)
Ploin 2002 0.0±9.0(54) 0.0±7.0(63)
O'Brien 2003† ROSSMAX blood pressure monitor  -4.5±9.5(52) -1.8±5.0(72)
Note: †: failed to pass validation protocol (judgment for both SBP and DBP).
Omron M6 (HEM-7001-E) 1.1± 4.0(89) -0.5±3.5(89)
Spengler KP7500 D
Omron M5-I (HEM-757-E)
Artsana CS 610
Citizen CH-432B
Microlife BP A100 Plus
Omron M6 (HEM-7001-E)
Omron 705IT
TONOPORT V
Omron HEM-907
Omron M1 Plus (HEM-4011C-E)
Omron M6 (HEM-7001-E)
Artsana CS410
Dinamap ProCare monitor
Tensoval duo control
SEINEX SE-9400
PMS mandaus
A&D UA-787
Omron M6 (HEM-7001-E)
Braun BP 2550 (UG)
Microlife WatchBP Home device
Microlife BP 3AC1-1
A&D UA-631 (UA-779 Life Source)
Stabil-O-Graph
Microlife BPA100 Plus
Rossmax (ME 701 series)
HEM-780REL
Omron MX3 Plus (HEM-742-E)
Omron M5-I
Omron M6 Comfort (HEM 7000-E)
Omron M7 (HEM-780-E)
Omron HEM-907
Calor® TensioSense BrasTM
Figure 4 Means and s.d. of errors in systolic BP in devices passing, or failing (marked dagger), the ESH-IP protocol.
Figure 5 Mean and single s.d. of errors in BP monitors in repeated studies of the same monitor.
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Journal of Human HypertensionIn general, we found devices performing badly do
so because of wide variation between differences
(large s.d.) rather than systematic over- or under-
estimation of BP (Figures 2–4). This is reflected in
the relatively stable mean difference, which leads to
a large number of additional measurements for
devices relative to only a small drop off in precision
(that is lower proportion of measurements within
5mmHg). This effect is negated by multiple read-
ings over multiple clinic visits. Yet, as a BP
approaches the threshold for diagnosis, this inaccu-
racy can substantially under- or overestimate the
burden of hypertension.
13 In addition, community
clinic-based validations were fewer and the
results much worse. This is particularly of concern,
as this setting is where devices are most often used
for the assessment and ongoing management of
hypertension.
However, it is worth noting that the change from
mercury to electronic BP measurement in practice
has led to no consistent change in mean BP after
their introduction, but there was a large and
significant fall in terminal digit preference suggest-
ing improved precision of recording with electronic
devices.
23
This study had a number of limitations: the
reproducibility of protocol testing is currently
unknown. We found no studies, which repeated
earlier validations. Some studies may have been
missed. Although the search of 5912 potentially
relevant records was comprehensive, with analysis
of 3356 potentially relevant records, studies in
which machines failed the validation are less
likely to be published, particularly if the manufac-
turer is involved in the funding. However,
missing such studies would have the effect of
worsening the results and hence would not alter
the conclusions. All validation studies found used
the standard cuff size. A significant proportion of
adults will need to use the larger cuff and yet
there is no evidence as to whether this will be
accurate. The analysis was limited by the lack of
reporting of proportional data in some cases.
Development of an international consensus on
minimal standards of reporting, including represen-
tations of proportional data, would go some way to
allowing comparison of devices under different
validation protocols. Our estimates of the proportion
within 5mmHg of the observed value may not be
accurate, because they assume a study-specific
normal distribution that leads to some degree of
inaccuracy, but were sufficient to inform the order-
ing of the figures.
The existing protocols have several limitations.
First, the procedure specifications are sometimes
ambiguous. For example, the AAMI protocol
allows a choice of data collection methods (simulta-
neous vs sequential) and a choice of data-analysis
methods, either of which may affect the final
results. Problems with validation protocol methods
not being detailed enough has earlier been cited as a
problem for interpretation.
24 Second, not all
protocols directly address the margin of error
between measurement and observed value, and
those that do allow margins of error as wide as 10
or 15mmHg, result in measurements that are
up to half the time 45mmHg from the observed
value in some monitors that pass protocols.
Third, we found few examples of the protocols
being tested in community settings (that is, real
clinics rather than artificial settings), and the
results from these studies were generally poor. This
is of concern because it may suggest that most
protocol studies overestimate device quality,
although we found too few community studies to
draw firm conclusions. Finally, the British
and American protocols are difficult or costly to
obtain, which could discourage further evaluation
of BP monitors. Further information on protocol
publications is available from the BHS website
(http://www.bhsoc.org/Blood_pressure_Publications.
stm).
Protocols that include measurements for a certain
proportion of readings to be within a certain value
and have unambiguous procedures could encourage
the manufacture of higher quality BP monitors.
Monitors need to be re-evaluated in community
settings (‘real clinics’) to verify their accuracy in
practice. The advent of a central, open access
repository of evaluation studies would be beneficial
to clinics and healthcare providers when choosing
digital monitors.
Current protocols for validating BP devices give
no guarantee of accuracy in clinical practice.
Devices may pass even rigorous protocols with as
few as 60% of readings within 5mmHg of the
observed value. The limited evidence available
suggests that performance in clinical practice will
be even worse than under protocol testing. BP
standards are essential to provide clinicians and
patients with accurate information on which to base
diagnostic and treatment decisions.
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